BRPI0817332A2 - Composição e método de ingrediente sensível estabilizado. - Google Patents

Composição e método de ingrediente sensível estabilizado.

Info

Publication number
BRPI0817332A2
BRPI0817332A2 BRPI0817332A BRPI0817332A2 BR PI0817332 A2 BRPI0817332 A2 BR PI0817332A2 BR PI0817332 A BRPI0817332 A BR PI0817332A BR PI0817332 A2 BRPI0817332 A2 BR PI0817332A2
Authority
BR
Brazil
Prior art keywords
composition
sensitive ingredient
stabilized
stabilized sensitive
ingredient
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Alfred Cimiluca
Sonsoles Arnal
Jorge Zambrano
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of BRPI0817332A2 publication Critical patent/BRPI0817332A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00Processes of treating or compounding macromolecular substances
    • C08J3/20Compounding polymers with additives, e.g. colouring
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L3/00Compositions of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08L3/02Starch; Degradation products thereof, e.g. dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2303/00Characterised by the use of starch, amylose or amylopectin or of their derivatives or degradation products
    • C08J2303/02Starch; Degradation products thereof, e.g. dextrin
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02Cellulose; Modified cellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
BRPI0817332 2007-09-24 2008-09-24 Composição e método de ingrediente sensível estabilizado. BRPI0817332A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99501907P 2007-09-24 2007-09-24
US4235008P 2008-04-04 2008-04-04
PCT/IB2008/053892 WO2009040750A1 (en) 2007-09-24 2008-09-24 Composition and method of stabilized sensitive ingredient

Publications (1)

Publication Number Publication Date
BRPI0817332A2 true BRPI0817332A2 (pt) 2015-03-24

Family

ID=40336439

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817332 BRPI0817332A2 (pt) 2007-09-24 2008-09-24 Composição e método de ingrediente sensível estabilizado.

Country Status (9)

Country Link
US (1) US9078824B2 (pt)
EP (1) EP2200590A1 (pt)
CN (1) CN101801349A (pt)
AU (1) AU2008303230B2 (pt)
BR (1) BRPI0817332A2 (pt)
CA (1) CA2700983C (pt)
MX (1) MX339598B (pt)
RU (1) RU2466741C2 (pt)
WO (1) WO2009040750A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8900557B2 (en) 2010-12-30 2014-12-02 Jr Chem, Llc Dental cleaning composition
CA2825917C (en) 2011-02-14 2016-08-30 The Procter & Gamble Company Filmcoated solid dosage forms comprising honey in the coating
ES2795291T3 (es) 2013-02-13 2020-11-23 Procter & Gamble Medicamento con sabor a anís
MA40071A (fr) 2014-07-01 2016-01-07 Probi Usa Inc Comprimés probiotiques bi-couche à double libération
WO2016057615A1 (en) * 2014-10-08 2016-04-14 Alva-Amco Pharmacal Companies, Inc. Composition for nap promotion
FR3047663A1 (fr) * 2016-02-12 2017-08-18 Idl Int Drug Licensing Comprime dispersible
PL3515413T3 (pl) 2016-09-26 2023-11-13 The Procter & Gamble Company Postać dawkowania zapewniająca przedłużoną ulgę
IT202200008018A1 (it) * 2022-04-22 2023-10-22 Calliero S P A Processo per la polverizzazione e stabilizzazione di oli essenziali comprendenti furanodieni
CN117017932B (zh) * 2023-08-24 2024-05-24 浙江和沐康医药科技有限公司 一种舒林酸片组合物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3453368A (en) * 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3480185A (en) * 1966-06-20 1969-11-25 Johnson & Johnson Charged effervescing agent and medicament dispensing metering valve-actuated aerosol container producing a dose of medicament and carbonation in water
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
JP2948317B2 (ja) 1991-05-28 1999-09-13 マクニール―ピーピーシー・インコーポレーテツド 噛める薬物投与用組成物
US5409709A (en) * 1991-11-29 1995-04-25 Lion Corporation Antipyretic analgesic preparation containing ibuprofen
US5674522A (en) * 1993-10-07 1997-10-07 Mcneil-Ppc, Inc. Beverage concentrate for drug delivery
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
JPH08325145A (ja) 1995-05-26 1996-12-10 Sumitomo Pharmaceut Co Ltd 安定なイソプロピルアンチピリン含有製剤
CA2269806C (en) 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
JP4384278B2 (ja) 1998-05-26 2009-12-16 東亜薬品株式会社 イブプロフェン含有粒剤
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6787164B2 (en) * 2000-02-23 2004-09-07 Bioselect Innovations, Inc. Composition and method for treating the effects of diseases and maladies
US20010043959A1 (en) * 2000-02-23 2001-11-22 Daniel Gelber Composition and method for treating the effects of diseases and maladies
JP2001261580A (ja) 2000-03-14 2001-09-26 Taisho Pharmaceut Co Ltd 用時溶解型医薬
US8282955B2 (en) * 2001-10-15 2012-10-09 Ferring B.V. Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease
RU2286156C2 (ru) * 2001-10-15 2006-10-27 Ферринг Бв Способ приготовления фармацевтической композиции, включающей в себя 5-аминосалициловую кислоту, для применения в лечении неспецифического язвенного колита и болезни крона
GB0206861D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Medicaments
AU2003219348A1 (en) 2002-04-22 2003-11-03 Adcock Ingram Intellectual Property (Proprietary) Limited Pharmaceutical compositions comprising a decongenstant and further active ingredients for treating cough and flu
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
JP4373649B2 (ja) 2002-08-01 2009-11-25 ロート製薬株式会社 経口用液剤
US20040101494A1 (en) * 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20050232987A1 (en) * 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
DE10359790A1 (de) 2003-12-19 2005-07-21 Bayer Healthcare Ag Brausezubereitung einer basischen arzneilich wirksamen Substanz
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
WO2006022996A2 (en) 2004-08-04 2006-03-02 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
NZ555909A (en) * 2004-12-13 2009-11-27 Mcneil Ppc Inc Compositions and methods for reducing the degradation of phenylephrine by oxygen
CA2591747A1 (en) * 2004-12-23 2006-06-29 Mcneil-Ppc, Inc. Orally disintegrating pharmaceutical compositions with sensory cue agents
CN1679525A (zh) * 2005-01-12 2005-10-12 复旦大学 复方对乙酰氨基酚口腔崩解片
US7851006B2 (en) * 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
EP1757274B1 (de) 2005-08-08 2012-07-25 Stada Arzneimittel Ag Brausezubereitung gegen Erkältungssymptome
CN1732938A (zh) * 2005-08-31 2006-02-15 上海医药(集团)有限公司 复方对乙酰氨基酚口腔崩解片
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20070160695A1 (en) * 2006-01-09 2007-07-12 Clouatre Dallas L Pharmaceutical preparations for treating hypertension and dyslipidemia with Allium ursinum and Allium sativum
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine

Also Published As

Publication number Publication date
US20090082316A1 (en) 2009-03-26
MX339598B (es) 2016-06-01
EP2200590A1 (en) 2010-06-30
AU2008303230B2 (en) 2014-07-03
CN101801349A (zh) 2010-08-11
RU2466741C2 (ru) 2012-11-20
CA2700983C (en) 2013-07-30
AU2008303230A1 (en) 2009-04-02
RU2010106225A (ru) 2011-11-10
CA2700983A1 (en) 2009-04-02
WO2009040750A1 (en) 2009-04-02
US9078824B2 (en) 2015-07-14
MX2010003250A (es) 2010-04-09

Similar Documents

Publication Publication Date Title
BRPI0906980A2 (pt) Composição de derivados e maleatados
BRPI0917358A2 (pt) formulação farmacêutica de liberação controlada e método.
DK3136030T3 (da) Fremgangsmåde til lyofilisering
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0809573A8 (pt) composição, e, método
BRPI0815588A2 (pt) Compostos de poliorganossiloxano-poliuréia e/ou de poliorganossilo-xano-poliuretano
BRPI0922440A2 (pt) dispositivo protético e método de fabricação do mesmo .
BRPI0920284A2 (pt) composição e método
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
BRPI0817332A2 (pt) Composição e método de ingrediente sensível estabilizado.
BRPI0813627A2 (pt) Peptídio antimicrobiano, composições e métodos de uso
DOP2010000044A (es) Derivado de oxopirazina y herbicida
BRPI0819232A2 (pt) composto heterocíclico e composição farmacêutica do mesmo
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
HRP20141261T1 (xx) Spojevi tioninija i njihove uporabe
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
DK2254873T3 (da) Benzodiazepinforbindelse og farmaceutisk sammensætning.
EP2079544A4 (en) ARSENIC ABSORBENT COMPOSITION AND METHODS OF USE
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0814167A2 (pt) Composição, e, método
EP2252669A4 (en) AZEOTROPARTIC COMPOSITION OF 1,1,1-TRIFLUOR-3-CHLOROPROPENE AND METHYL ACETATE
EP2116535A4 (en) GLUCOKINASE ACTIVATING SUBSTANCE
BRPI0813922A2 (pt) composições de inibição de influenza e métodos.
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL